Elevation Oncology (ELEV) Climbs 57%(Updated – May 26, 2023 10:50 AM EDT)Elevation Oncology (ELEV) Climbs 57%Hedge fund Point72 recently disclosed an 8.7% stake in the companyToday’s gain appear related to early-stage data for its treatment of gastric cancer at ASCO. The abstract was for “First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.”

Source: www.investing.com